Gene therapy: therapeutic applications and relevance to pathology
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lister Hill National Center for Biomedical Communications, US National Library of Medicine, National Institutes of Health, Department of Health and Human Services, US National Library. Genetics Home Reference: Handbook. July 2011 (cited July 2011). http://ghr.nlm.nih.gov/handbook/therapy/genetherapy2011
Friedmann, 1992, Gene therapy of cancer through restoration of tumor-suppressor functions?, Cancer, 70, 1810, 10.1002/1097-0142(19920915)70:4+<1810::AID-CNCR2820701624>3.0.CO;2-3
Chinnasamy, 2004, Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)- nitrosourea or temozolomide, Hum Gene Ther, 15, 758, 10.1089/1043034041648417
Kiem, 2010, Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo, Gene Ther, 17, 37, 10.1038/gt.2009.118
Fischer, 2002, Gene therapy of severe combined immunodeficiencies, Nat Rev Immunol, 2, 615, 10.1038/nri859
US Food and Drug Administration. Cellular and Gene Therapy Guidances. February 2011 (cited July 2011). http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/default.htm
National Institute of Health (NIH), Office of Science Policy. Recombinant DNA Advisory Committee (RAC). March 2011 (cited July 2011). http://oba.od.nih.gov/rdna_rac/rac_about.html
Australian Government, Department of Health and Ageing. Therapeutic Goods Administration (TGA). July 2011 (cited July 2011). http://www.tga.gov.au/about/index.htm
Australian Government, Department of Health and Ageing. Office of the Gene Technology Regulator (OGTR). Guidelines. July 2011 (cited July 2011). http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/guidelines-1
Keller, 1993, Hematopoietic commit-ment during embryonic stem cell differentiation in culture, Mol Cell Biol, 13, 473, 10.1128/MCB.13.1.473
Odorico, 2001, Multilineage differentiation from human embryonic stem cell lines, Stem Cells, 19, 193, 10.1634/stemcells.19-3-193
Modlich, 2009, Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors, Mol Ther, 17, 1919, 10.1038/mt.2009.179
Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat Biotechnol, 24, 687, 10.1038/nbt1216
Sastry, 2003, Certification assays for HIV-1-based vectors: frequent passage of gag sequences without evidence of replica-tion-competent viruses, Mol Ther, 8, 830, 10.1016/j.ymthe.2003.08.003
Cavazzana-Calvo, 2000, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, 669, 10.1126/science.288.5466.669
Aiuti, 2002, Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning, Science, 296, 2410, 10.1126/science.1070104
Aiuti, 2002, Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement, NatMed, 8, 423
Gaspar, 2004, Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector, Lancet, 364, 2181, 10.1016/S0140-6736(04)17590-9
Ginn, 2005, Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia, Med J Aust, 182, 458, 10.5694/j.1326-5377.2005.tb06785.x
Ferrua, 2010, Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency, Curr Opin Allergy Clin Immunol, 10, 551, 10.1097/ACI.0b013e32833fea85
Hacein-Bey-Abina, 2010, Efficacy of gene therapy for X-linked severe combined immunodeficiency, N Engl J Med, 363, 355, 10.1056/NEJMoa1000164
Ponnazhagan, 1997, Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells, Hum Gene Ther, 8, 275, 10.1089/hum.1997.8.3-275
Hacein-Bey-Abina, 2003, A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency, N Engl J Med, 348, 255, 10.1056/NEJM200301163480314
Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J Clin Invest, 118, 3143, 10.1172/JCI35798
Cavazzana-Calvo, 2010, Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia, Nature, 467, 318, 10.1038/nature09328
Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation ofMDS1-EVI1, PRDM16 or SETBP1, NatMed, 12, 401
Stein, 2010, Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, Nat Med, 16, 198, 10.1038/nm.2088
Persons, 2011, Solving the problem of gamma-retroviral vectors containing long terminal repeats, Mol Ther, 19, 229, 10.1038/mt.2010.305
Boztug, 2010, Stem-cell gene therapy for the Wiskott-Aldrich syndrome, N Engl J Med, 363, 1918, 10.1056/NEJMoa1003548
Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003
Cartier, 2009, Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleuko-dystrophy, Science, 326, 818, 10.1126/science.1171242
Naldini, 1996, In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector, Science, 272, 263, 10.1126/science.272.5259.263
Prostate Cancer Foundation of Australia. Prostate Cancer Statistics. July 2011 (cited July 2011). http://www.prostate.org.au/articleLive/pages/Prostate-Cancer-Statistics.html
Both, 2009, Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment, Curr Opin Mol Ther, 11, 421
Both, 2009, Gene-directed enzyme prodrug therapy for cancer: a glimpse into the future?, Discov Med, 8, 97
Berges, 1995, Implication of cell kinetic changes during the progression of human prostatic cancer, Clin Cancer Res, 1, 473
Patel, 2009, A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984], Mol Ther, 17, 1292, 10.1038/mt.2009.80
Lockett, 1997, Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors, Clin Cancer Res, 3, 2075
Both, 2004, Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector, Immunol Cell Biol, 82, 189, 10.1046/j.0818-9641.2004.01223.x
Zaiss, 2009, The influence of innate and pre-existing immunity on adenovirus therapy, J Cell Biochem, 108, 778, 10.1002/jcb.22328
Martiniello-Wilks, 2004, Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease, J Gene Med, 6, 43, 10.1002/jgm.474
Martiniello-Wilks, 2004, Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer, J Gene Med, 6, 1343, 10.1002/jgm.629
Wang, 2004, Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus, Gene Ther, 11, 1559, 10.1038/sj.gt.3302308
Rogulski, 2000, Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization, Hum Gene Ther, 11, 67, 10.1089/10430340050016166
Freytag, 2007, Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer, Mol Ther, 15, 1016, 10.1038/mt.sj.6300120
Freytag, 2007, Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treat-ment of prostate cancer, Mol Ther, 15, 636, 10.1038/sj.mt.6300068
Freytag, 2003, Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combina-tion with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediateto high-risk prostate cancer, Cancer Res, 63, 7497
US National Institutes of Health (NIH). ClinicalTrials.gov. July 2011 (cited July 2011). http://clinicaltrials.gov
Freytag, 2007, Prostate cancer gene therapy clinical trials, Mol Ther, 15, 1042, 10.1038/sj.mt.6300162
Khatri, 2009, Cytosine deaminase-uracil phosphor-ibosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines, Clin Cancer Res, 15, 2323, 10.1158/1078-0432.CCR-08-2039
de Vrij, 2010, Adenovirus-derived vectors for prostate cancer gene therapy, Hum Gene Ther, 21, 795, 10.1089/hum.2009.203
AidsInfo. Clinical Guidelines Portal. July 2011 (cited July 2011). www.aidsinfo.nih.gov/Guidelines/Default.aspx
Robb, 2008, Failure of the Merck HIV vaccine: an uncertain step forward, Lancet, 372, 1857, 10.1016/S0140-6736(08)61593-7
Fanning, 2003, Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen, J Gene Med, 5, 645, 10.1002/jgm.436
Fanning, 2006, Gene-expressed RNA as a therapeutic: issues to consider, using ribozymes and small hairpin RNA as specific examples, Handb Exp Pharmacol, 173, 289, 10.1007/3-540-27262-3_14
Mitsuyasu, 2011, Phase I/II clinical trials using gene-modified adult hematopoietic stem cells for HIV: lessons learnt
Symonds, 2010, The use of cell-delivered gene therapy for the treatment of HIV/AIDS, Immunol Res, 48, 84, 10.1007/s12026-010-8169-7
Mitsuyasu, 2009, Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells, Nat Med, 15, 285, 10.1038/nm.1932
Macpherson, 2005, Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lympho-cytes in HIV-infected patients, J Gene Med, 7, 552, 10.1002/jgm.705
Amado, 2004, Anti-human immuno-deficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients, Hum Gene Ther, 15, 251, 10.1089/104303404322886101
Prior, 2005, Experience and strategy for the molecular testing of Duchenne muscular dystrophy, J Mol Diagn, 7, 317, 10.1016/S1525-1578(10)60560-0
Bushby, 2004, Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands, Neuromuscul Disord, 14, 526, 10.1016/j.nmd.2004.05.006
Manzur, 2008, Glucocorticoid corticosteroids for Duchenne muscular dystrophy, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD003725.pub3
Eagle, 2002, Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation, Neuromuscul Disord, 12, 926, 10.1016/S0960-8966(02)00140-2
Wang, 2009, Gene therapy in large animal models of muscular dystrophy, ILAR J, 50, 187, 10.1093/ilar.50.2.187
Trollet, 2009, Gene therapy for muscular dystrophy: current progress and future prospects, Expert Opin Biol Ther, 9, 849, 10.1517/14712590903029164
Malik, 2010, Gentamicin-induced read-through of stop codons in Duchenne muscular dystrophy, Ann Neurol, 67, 771, 10.1002/ana.22024
Malik, 2010, Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy, Ther Adv Neurol Disord, 3, 379, 10.1177/1756285610388693
Miura, 2006, Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?, Trends Mol Med, 12, 122, 10.1016/j.molmed.2006.01.002
Aartsma-Rus, 2010, New insights in gene-derived therapy: the example of Duchenne muscular dystrophy, Ann N Y Acad Sci, 1214, 199, 10.1111/j.1749-6632.2010.05836.x
Wilton, 1999, Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleo-tides, Neuromuscul Disord, 9, 330, 10.1016/S0960-8966(99)00010-3
Wilton, 2007, Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript, Mol Ther, 15, 1288, 10.1038/sj.mt.6300095
Wilton, 2010, Splice modification to restore functional dystro-phin synthesis in Duchenne muscular dystrophy, Curr Pharm Des, 16, 988, 10.2174/138161210790883480
Mendell, 2010, Molecular therapeutic strategies targeting duchenne muscular dystrophy, J Child Neurol, 25, 1145, 10.1177/0883073810371005
Monaco, 1988, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, 2, 90, 10.1016/0888-7543(88)90113-9
Klein, 1992, Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers, Am J Hum Genet, 50, 950
Sherratt, 1993, Exon skipping and translation in patients with frameshift deletions in the dystrophin gene, Am J Hum Genet, 53, 1007
Mann, 2001, Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse, Proc Natl Acad Sci USA, 98, 42, 10.1073/pnas.98.1.42
Mann, 2002, Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy, J Gene Med, 4, 644, 10.1002/jgm.295
McClorey, 2006, Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD, Gene Ther, 13, 1373, 10.1038/sj.gt.3302800
Aartsma-Rus, 2003, Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients, Hum Mol Genet, 12, 907, 10.1093/hmg/ddg100
Chelly, 1988, Transcription of the dystrophin gene in human muscle and non-muscle tissue, Nature, 333, 858, 10.1038/333858a0
Arechavala-Gomeza, 2010, Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression, Neuropathol Appl Neurobiol, 36, 265, 10.1111/j.1365-2990.2009.01056.x
Fletcher, 2007, Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse, Mol Ther, 15, 1587, 10.1038/sj.mt.6300245
Gebski, 2003, Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle, Hum Mol Genet, 12, 1801, 10.1093/hmg/ddg196
Alter, 2006, Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nat Med, 12, 175, 10.1038/nm1345
Lu, 2003, Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse, Nat Med, 9, 1009, 10.1038/nm897
Lu, 2005, Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles, Proc Natl Acad Sci USA, 102, 198, 10.1073/pnas.0406700102
Yokota, 2009, Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs, Ann Neurol, 65, 667, 10.1002/ana.21627
Goyenvalle, 2010, Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping, Mol Ther, 18, 198, 10.1038/mt.2009.248
van Deutekom, 2007, Local dystrophin restoration with antisense oligonucleotide PRO051, N Engl J Med, 357, 2677, 10.1056/NEJMoa073108
Goemans, 2011, Systemic adminis-tration of PRO051 in Duchenne’s muscular dystrophy, NEngl J Med, 364, 1513, 10.1056/NEJMoa1011367
Kinali, 2009, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol, 8, 918, 10.1016/S1474-4422(09)70211-X
Arechavala-Gomeza, 2007, Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle, Hum Gene Ther, 18, 798, 10.1089/hum.2006.061
Cirak, 2011, Systemic administrtation of the morpholino antisense oligomer AVI-4658 induces exon skip-ping and dystrophin expression in Duchenne muscular dystrophy
Fletcher, 2006, Dystrophin expression inthe mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide, J Gene Med, 8, 207, 10.1002/jgm.838
Heemskerk, 2009, In vivo comparison of 2’-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping, J Gene Med, 11, 257, 10.1002/jgm.1288
Aartsma-Rus, 2011, The risks of therapeutic misconception and individual patient (n=1) ‘trials’ in rare diseases such as Duchenne dystrophy, Neuromuscul Disord, 21, 13, 10.1016/j.nmd.2010.09.012
Evans, 1989, Canine hemophilia B resulting from a point mutation with unusual consequences, Proc Natl Acad Sci USA, 86, 10095, 10.1073/pnas.86.24.10095
Hough, 2002, Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia, Thromb Haemost, 87, 659, 10.1055/s-0037-1613063
Lozier, 2002, The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion, Proc Natl Acad Sci USA, 99, 12991, 10.1073/pnas.192219599
Lozier, 1999, The rhesus macaque as an animal model for hemophilia B gene therapy, Blood, 93, 1875, 10.1182/blood.V93.6.1875.406k16_1875_1881
Qiu, 1996, Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients, Chin Med J (Engl), 109, 832
Viiala, 2009, Gene therapy for hemophilia: clinical trials and technical tribulations, Semin Thromb Hemost, 35, 81, 10.1055/s-0029-1214151
Herzog, 1999, Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector, Nat Med, 5, 56, 10.1038/4743
Snyder, 1999, Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors, Nat Med, 5, 64, 10.1038/13518
Mount, 2002, Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy, Blood, 99, 2670, 10.1182/blood.V99.8.2670
Nathwani, 2006, Self-complementary adenoassociated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood, 107, 2653, 10.1182/blood-2005-10-4035
Vandendriessche, 2007, Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy, J Thromb Haemost, 5, 16, 10.1111/j.1538-7836.2006.02220.x
Jiang, 2006, Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs, Blood, 108, 107, 10.1182/blood-2005-12-5115
Manno, 2006, Successfultransduction ofliverin hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med, 12, 342, 10.1038/nm1358
Mingozzi, 2007, CD8(+) T-cell responses to adenoassociated virus capsid in humans, Nat Med, 13, 419, 10.1038/nm1549
Schuettrumpf, 2006, Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial, Mol Ther, 13, 1064, 10.1016/j.ymthe.2006.03.002
Vandenberghe, 2006, Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid, Nat Med, 12, 967, 10.1038/nm1445
Mingozzi, 2011, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, Nat Rev Genet, 12, 341, 10.1038/nrg2988
Blaese, 1995, T Lymphocyte-directed gene therapy for ADA—SCID: initial trial results after 4 years, Science, 270, 475, 10.1126/science.270.5235.475
Branca, 2005, Gene therapy: cursed or inching towards credibility?, Nat Biotechnol, 23, 519, 10.1038/nbt0505-519